Detecting High-Grade Cervical Intraepithelial Neoplasia: Primary High-Risk HPV Screening with Cytology Feasible Alternative to Cytological Screening

Share this content:

(ChemotherapyAdvisor) – A study of 25,871 women has found that the most effective approach for cervical screening is to conduct primary high-risk human papilloma virus (hrHPV) screening and, if positive for grade 3 or worse high-grade cervical intraepithelial neoplasia (CIN3+), repeat cytology, investigators concluded in the British Journal of Cancer February 28.

The study sought to determine how best to use hrHPV testing — which is more sensitive than cytology for detecting CIN3+ — for cervical screening. Women 29–61 years of age enrolled in a population-based cohort study were offered both cytology and hrHPV testing. Repeat testing after one and/or two years was recommended for women who were hrHPV positive with normal cytology. If results indicated abnormal cytology and/or a second hrHPV test was positive, they were referred for colposcopy. The primary outcome measure was CIN3+.

The investigators found that CIN3+ risk in women who were hrHPV-positive with abnormal cytology was 42.2%; those with normal cytology had a much lower risk, 5.22% (95% CI: 3.72–7.91). In women with hrHPV-positive normal cytology, an additional cytology step after one year reduced CIN3+ risk to 1.6% if the repeat test was normal.

By using this approach, only women with the highest CIN3+ risks would be referred for further tests, reducing unnecessary examinations.


Related Resources

You must be a registered member of Cancer Therapy Advisor to post a comment.

Sign Up for Free e-newsletters

Regimen and Drug Listings


Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Prostate Cancer Regimens Drugs
Rare Cancers Regimens
Renal Cell Carcinoma Regimens Drugs
Skin Cancer Regimens Drugs
Urologic Cancers Regimens Drugs